Quintrio
Home

Stock overview

GH Research PLC Ordinary Shares

GHRS

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Last trade $17.95
Day change -$0.80 (-4.27%)
Day range $17.61 – $18.91
Volume 245,845
Market cap $1.29B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for GHRS.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for GHRS.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments

Five psychedelic biotech companies are advancing toward Phase 3 trials for treating depression and anxiety disorders. Helus Pharma reported positive Phase 2a results for SPL026 in major depressive disorder published in Nature Medicine. AtaiBeckley, Definium Therapeutics, GH Research, and LB Pharmaceuticals are all progressing late-stage clinical programs with multiple Phase 3 readouts expected in 2026, signaling the sector's maturation toward regulatory approval.

Benzinga

Stock Market Today: S&P 500, Nasdaq, WTI Crude Futures Advance After US Strike On Venezuela— GH Research, Vertiv Holdings, Nukkleus In Focus (UPDATED)

U.S. stock futures rose on Monday as major indices opened the first full trading week of 2026 higher. Following the U.S. strike on Venezuela and removal of President Maduro, crude oil prices fluctuated around $57.29 per barrel. Several stocks gained attention: Vertiv Holdings jumped on an upgrade, GH Research soared on FDA update news, Nukkleus rose after acquiring Israeli defense software, Ironwood advanced on positive FY26 guidance, and Brand Engagement Network climbed on a new vendor agreement. JPMorgan's outlook suggests continued but challenged strength in U.S. equities, with potential 10-15% corrections offset by year-end gains driven by AI-related spending.

GlobeNewswire Inc.

GH Research Announces Global Pivotal Program Plans and Further Development Updates

GH Research submitted a complete response to FDA's clinical hold on GH001, with one remaining issue regarding respiratory tract histology in rats. The Phase 2b trial showed a 73% remission rate at 6 months for treatment-resistant depression, with no serious adverse events and promising treatment outcomes.

GlobeNewswire Inc.

GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule

GH Research PLC, a clinical-stage biopharmaceutical company, announced the submission of its complete response to the FDA regarding the clinical hold on its Investigational New Drug Application for GH001, its lead product candidate for treating treatment-resistant depression.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.